William "Will" Pendergraft III, MD, PhD

The Best Doctors in America Peer selected 2017-2018

Assistant Professor of Medicine

Specialty Areas: Glomerular disease, vasculitis (primary focus: ANCA vasculitis), lupus nephritis, drug-induced autoimmune disease.

BA: University of North Carolina at Chapel Hill, 1997
PhD: Molecular and Cellular Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 2003
MD: University of North Carolina School of Medicine, 2008
Residency: Categorical Internal Medicine, University of California, San Francisco, 2010
Fellowship: Joint Nephrology Fellowship Program, Brigham and Women’s Hospital and Massachusetts General Hospital, 2013
Visiting Postdoctoral Scholar: The Broad Institute of Harvard and MIT, 2011-present
Assistant Professor of Medicine: University of North Carolina, 2013-present

Board Certifications: Internal Medicine and Nephrology

Dr. Pendergraft’s professional mission is to:

  • Provide world-renowned expert medical care for patients with kidney disease
  • Educate and excite trainees about nephrology
  • Conduct translational and clinical research in order to cure autoimmune disease and prevent relapse with a special emphasis on autoimmune diseases that affect the kidneys

Currently, Dr. Pendergraft’s research program includes:

  • Understanding response to therapy and relapse in lupus nephritis and ANCA vasculitis using high-resolution systems-level tools (epigenetic, transcriptomic, metabolomic, proteomic and microbiomic)
  • Repurposing FDA-approved drugs for use in lupus nephritis and ANCA vasculitis
  • Translational studies aimed at understanding drug-induced forms of ANCA vasculitis
  • Clinical trials of existing and novel biologic therapies for lupus nephritis and ANCA vasculitis
  • Clinical data analysis of large and unique cohorts of patients with either lupus nephritis, ANCA vasculitis or idiopathic membranous nephropathy
  • In-depth characterization of rituximab use and development of guidelines to prevent and manage adverse events
Selected Bibliography:
  1. Pendergraft, W.F., Niles, J.L. “Trojan horses: drug culprits associated with anti-neutrophil cytoplasmic autoantibody vasculitis.” Current Opinion in Rheumatology, 26(1): 42-49, January 2014.
  2. Ramirez-Ortiz, Z.G., Pendergraft, W.F., Prasad, A., Byrne, M.H., Iram, T., Blanchette, C.J., Luster, A.D., Hacohen, N., Khoury, J.E., Means, T.K. “The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity.” Nature Immunology, 14(9): 917-26, September 2013.
  3. Pendergraft, W.F., McGrath, M.M., Murphy, A.P., Murphy, P., Laliberte, K.A., Greene, M.F., Niles, J.L. “Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.” Annals of the Rheumatic Diseases, 72(12): 2051-3, December 2013.
  4. Arazi, A., Pendergraft, W.F., Ribeiro, R.M., Perelson, A.S., Hacohen, N. “Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.” Seminars in Immunology, 25(3): 193-200, October 2013.
  5. Ciavatta, D.J., Yang, J.J., Preston, G.A., Badhwar, A.K., Xiao, H., Hewins, P., Nester, C.M., Pendergraft, W.F., Magnuson, T.R., Jennette, J.C., Falk, R.J. “Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.” Journal of Clinical Investigation, 120(9): 3209-19, September 2010.
  6. Pendergraft, W.F., Pressler, B.M., Jennette, J.C., Falk, R.J., Preston, G.A. “Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.” Journal of Molecular Medicine, Vol. 83(1): 12-25, January 2005.
  7. Pendergraft, W.F., Preston, G.A., Shah, R.R., Tropsha, A., Carter, C., Jennette, J.C., Falk, R.J. “ Autoimmunity is triggered by cPR-3(105-201), a protein complementary to the human autoantigen Proteinase-3.” Nature Medicine, Vol. 10(1): 72-79, January 2004.
  8. Pendergraft, W.F., Rudolph, E.H., Falk, R.J., Jahn, J.E., Grimmler, M., Hengst, L., Jennette, J.C., Preston, G.A. “Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis.” Kidney International, Vol. 65(1): 75-84, January 2004.
  9. Pendergraft, W.F., Alcorta, D.A., Segelmark, M., Yang, J.J., Tuttle, R., Jennette, J.C., Falk, R.J., Preston, G.A. “ANCA antigens, proteinase 3 (PR3) and myeloperoxidase (MPO), are not expressed in endothelial cells.” Kidney International, Vol. 57(5): 1981-1990, May 2000.

View list of all publications on PubMed